GSK_ Annual_Report_2021-22

GlaxoSmithKline Pharmaceuticals Limited | Annual Report 2021-22 Notes to the Standalone Financial Statements for the year ended March 31, 2022 154 B. Fair Value Hierarchy This section explains the judgements and estimates made in determining the fair values of the financial instruments that are (a) recognised and measured at fair value and (b) measured at amortised cost and for which fair values are disclosed in the Standalone Financial Statements. (a) Financial instruments that are recognised and measured at fair value To provide an indication about the reliability of the inputs used in determining fair value, the Company has classified its financial instruments into the three levels prescribed under the accounting standard. Level 1 : It includes financial instruments measured using quoted prices. Level 2 : The fair value of financial instruments that are not traded in an active market is determined using valuation techniques which maximise the use of observable market data and rely as little as possible on entity-specific estimates. If all significant inputs required to fair value an instrument are observable, the instrument is included in level 2. Level 3 : Valuation techniques for which the lowest level input that is significant to the fair value measurement is directly or indirectly observable. (a) Fair value of financial assets measured at Fair value through Profit and loss ( ` in lakhs) Financial assets measured at Fair value Fair value hierarchy Fair value as at Valuation technique(s) and key input(s) As at March 31, 2022 As at March 31, 2021 Financial assets Level -1 Net asset value published by Mutual Fund Investments Mutual fund investments 365,59.23 - Total financial assets 365,59.23 - (b) Fair value of financial assets and liabilities measured at amortised cost* ( ` in lakhs) As at March 31, 2022 As at March 31, 2021 Financial assets Security Deposits Carrying value 6,94.06 8,06.08 Fair value 6,94.06 8,06.08 Margin money/ Deposit against bank guarantee Carrying value 4,10.78 4,01.47 Fair value 4,10.78 4,01.47 Loan to Related Parties Carrying value 204,60.00 - Fair value 204,60.00 - *Excludes investments in subsidiary